Capricor Therapeutics Inc Stock
Capricor Therapeutics Inc took a tumble today and lost -€0.299 (-8.260%).
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | -8.260% | -80.756% | -84.172% | -53.487% | -86.998% | -17.040% | -9.375% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
News
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- Capricor Therapeutics says it is in active discussions with the FDA to support approval of deramiocel
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review